Trial · NCT07895758
Assessment of the Seasonality of Depressive Symptoms in Adolescents
NCT07895758, Not yet recruiting, University Hospital, Rouen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Assessment of the Seasonality of Depressive Symptoms in Adolescents. Trials, record NCT07895758. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895758
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Assessment of the Seasonality of Depressive Symptoms in Adolescents
- NCT number
- NCT07895758
- Status
- Not yet recruiting
- Enrollment
- 210 participants, estimated
- Lead sponsor
- University Hospital, Rouen
- Conditions
- Depressive Symptoms
- Interventions
- Measuring the intensity of the seasonality of depressive symptoms in adolescents
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To assess the intensity of the seasonality of depressive symptoms in adolescents receiving care for child psychiatric reasons at the Rouen University Hospital | 1 day | The intensity of the seasonality of depressive symptoms will be measured using the continuous Global Seasonality Score (GSS) from the SPAQ. The GSS is the sum of six items related to seasonal variation (sleep, social activity, mood, weight, appetite, and energy), each rated from 0 to 4, resulting in a total score ranging from 0 to 24. A high score indicates greater reported seasonal variations |
| Secondary | Determine the proportion of adolescents with a profile consistent with seasonal affective disorder, based on the Global Seasonality Score (GSS) from the SPAQ. | 1 day | Proportion of adolescents whose responses to the SPAQ questionnaire correspond to a profile consistent with seasonal affective disorder (SAD) or a subsyndromal profile (S-SAD). The classification is based on two complementary elements: * The GSS: the seasonality score, ranging from 0 to 24. * Perceived impairment: the extent to which seasonal variations affect the adolescent's life, assessed via a specific item in the questionnaire. The classification will be based on the following profiles : 1. Profile consistent with SAD (Seasonal Affective Disorder) \- GSS ≥ 11 and at least moderate impairment. The adolescent reports significant seasonal variations, accompanied by at least a moderate impact. 2. Profile compatible with S-SAD (Subsyndromal Seasonal Affective Disorder) Two scenarios are possible: * A GSS (Global Seasonality Score) between 8 and 10, accompanied by at least mild impairment. * A GSS ≥ 11, but without significant impairment. Seasonal variations are present, but their |
| Secondary | Describe the clinical and sociodemographic characteristics associated with seasonal variation in depressive symptoms (age, sex, psychiatric history, context of hospitalization, family psychiatric history (especially disorders)). | 1 day | Determination of factors associated with seasonality (age, sex, medical history, reason for hospitalization, and family and personal psychiatric history). |
| Secondary | Describe the clinical and sociodemographic characteristics associated with seasonal variation in depressive symptoms (age). | 1 day | Determination of factors associated with seasonality (age) |
| Secondary | Describe the clinical and sociodemographic characteristics associated with seasonal variation in depressive symptoms (sex). | 1 day | Determination of factors associated with seasonality (sex). |
| Secondary | Describe the clinical and sociodemographic characteristics associated with seasonal variation in depressive symptoms (psychiatric history). | 1 day | Determination of factors associated with seasonality (psychiatric history). |
| Secondary | Describe the clinical and sociodemographic characteristics associated with seasonal variation in depressive symptoms (context of hospitalization). | 1 day | Determination of factors associated with seasonality (reason for hospitalization). |
| Secondary | Describe the clinical and sociodemographic characteristics associated with seasonal variation in depressive symptoms (medical history). | 1 day | Determination of factors associated with seasonality (medical history). |
| Secondary | To evaluate the feasibility of using the SPAQ in an adolescent population hospitalized in a pediatric setting. | 1 day | The completion rate for the SPAQ questionnaire is an important indicator of the feasibility of its use among adolescents hospitalized in pediatric settings. It makes it possible to measure the proportion of questionnaires that are filled out-ideally, with a sufficient level of completeness to be usable. The completion rate for the SPAQ questionnaire is number of completed questionnaires out of the number of questionnaires for which administration was undertaken. The feasibility of using the SPAQ will be assessed, in particular, by the questionnaire completion rate, defined as the proportion of fully completed and usable questionnaires out of the total number of questionnaires that were initiated. |
| Secondary | To evaluate the relevance of using the SPAQ in an adolescent population hospitalized in a pediatric setting (Taken Time). | 1 day | The time taken to complete the questionnaire will make it possible to assess its ease of use. The administration time is determined by subtracting the start time from the end time to obtain the duration, in minutes, taken to complete the questionnaire. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895758
GET https://conductscience.org/api/trials/v1/NCT07895758/registered